Your browser doesn't support javascript.
loading
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan.
Uchimoto, Taizo; Komura, Kazumasa; Fukuokaya, Wataru; Kimura, Takahiro; Takahashi, Kazuhiro; Yano, Yusuke; Nishimura, Kazuki; Nakamori, Keita; Fujiwara, Yuya; Matsunaga, Tomohisa; Tsutsumi, Takeshi; Tsujino, Takuya; Maenosono, Ryoichi; Yoshikawa, Yuki; Taniguchi, Kohei; Tanaka, Tomohito; Uehara, Hirofumi; Hirano, Hajime; Nomi, Hayahito; Takahara, Kiyoshi; Inamoto, Teruo; Egawa, Shin; Azuma, Haruhito.
Afiliación
  • Uchimoto T; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Komura K; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Fukuokaya W; Translational Research Program, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Kimura T; Department of Urology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
  • Takahashi K; Department of Urology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
  • Yano Y; Department of Urology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
  • Nishimura K; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Nakamori K; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Fujiwara Y; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Matsunaga T; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Tsutsumi T; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Tsujino T; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Maenosono R; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Yoshikawa Y; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Taniguchi K; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Tanaka T; Translational Research Program, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Uehara H; Translational Research Program, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Hirano H; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Nomi H; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Takahara K; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Inamoto T; Department of Urology, Fujita-Health University School of Medicine, Nagoya 470-1192, Japan.
  • Egawa S; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
  • Azuma H; Department of Urology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
Cancers (Basel) ; 13(14)2021 Jul 15.
Article en En | MEDLINE | ID: mdl-34298768
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza